D-0165-2020 Class II Terminated

Recalled by AVKARE Inc. — Pulaski, TN

FDA drug recall D-0165-2020 was initiated by AVKARE Inc. on Oct 17, 2019 and is designated Class II. Reason for recall: CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API The recall status is terminated (terminated Oct 21, 2020). Affected quantity: 1351 bottles.

Recall details

Product Type
Drugs
Report Date
Nov 6, 2019
Initiation Date
Oct 17, 2019
Termination Date
Oct 21, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1351 bottles

Product description

AVKARE Ranitidine Hydrochloride Capsules 300 mg 500 Capsules Rx Only NDC 42291-736-50 UPC 342291736504 Manufactured for: AvKARE, Inc. Pulaski, TN 38478

Reason for recall

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Distribution pattern

CO, MO

Code information

Lot 17709 Exp.01/31/2020 Lot 18460 Exp.02/29/2020 Lot 19853 Exp.09/30/2020 Lot 22362 Exp.11/30/2020 Lot 22579 Exp.11/30/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0165-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0165-2020. Report a data issue: hello@regdatalab.com.